Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
University of Michigan Rogel Cancer Center
Eli Lilly and Company
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
University of Alabama at Birmingham
QED Therapeutics, a BridgeBio company
Academic and Community Cancer Research United
EpicentRx, Inc.
Novo Nordisk A/S
EMD Serono
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Concordia Laboratories Inc.
Allina Health System
New Mexico Cancer Research Alliance
Stanford University